Exosome Diagnostics Revenue and Competitors
Estimated Revenue & Valuation
- Exosome Diagnostics's estimated annual revenue is currently $17.8M per year.
- Exosome Diagnostics received $30.0M in venture funding in July 2017.
- Exosome Diagnostics's estimated revenue per employee is $155,000
- Exosome Diagnostics's total funding is $112.1M.
Employee Data
- Exosome Diagnostics has 115 Employees.
- Exosome Diagnostics grew their employee count by 5% last year.
Exosome Diagnostics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Scientific Officer and VP | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Head Medical Affairs | Reveal Email/Phone |
4 | Director Commercial | Reveal Email/Phone |
5 | Senior Manager, Assay Transfer, Operations | Reveal Email/Phone |
6 | Manager, LIMS and Automation | Reveal Email/Phone |
7 | Senior Manager, Research and Development | Reveal Email/Phone |
8 | Sr Quality and Regulatory Manager | Reveal Email/Phone |
9 | Human Resources Manager (HRBP) | Reveal Email/Phone |
10 | Program Management Consulting | Reveal Email/Phone |
Exosome Diagnostics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Exosome Diagnostics?
Exosome Diagnostics, Inc. is commercializing minimally invasive molecular diagnostics in blood and urine to enable doctors to select optimal therapies for cancer and other diseases. Exosomes are lipid bilayer covered microvesicles shed by solid tumors into body fluids, such as blood and urine. Exosomes contain nucleic acid profiles of cancers and other diseases. In published studies, Exosome Diagnostics has demonstrated the ability to extract exosomes from the blood and urine of patients, and to detect with high sensitivity and specificity key genes and gene mutations associated with a variety of cancers.
keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals
$112.1M
Total Funding
115
Number of Employees
$17.8M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Exosome Diagnostics News
Researchers from UQ identified and validated exosomal protein and ... The global ovarian cancer diagnostics market is expected to reach $1.9...
Future Market Insights in its recent research report titled Exosome Diagnostic and Therapeutics Market: Global Industry Analysis...
Key Players Mentioned in the Exosome Diagnostic And Therapeutic Market Research Report: Exosome Diagnostics Inc., Thermo Fisher Scientific Inc.,...
The Global Exosome Diagnostics and Therapeutics Market 2019 recently published report provides a unique overview market for the ...
Exosome Diagnostics and Therapeutics market research report 2015-2024 helps businessman/investor avoiding unpleasant surprises. Intuition and experience ...
Other Companies in Waltham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $29.4M | 117 | -28% | N/A |
#2 | $23.9M | 119 | 8% | $113M |
#3 | $38.7M | 119 | 2% | $5.4M |
#4 | $16.7M | 119 | 13% | $63.4M |
#5 | $16.3M | 125 | 58% | N/A |
Exosome Diagnostics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2010-05-13 | $20.0M | Undisclosed | NGN Capital, Forbion Capital Partners | Article |
| 2010-08-31 | $20.0M | Undisclosed | NGN Capital, Forbion Capital Partners | Article |
| 2014-03-12 | $27.0M | B | QIAGEN | Article |
| 2015-09-03 | $17.6M | B | Multiple | Article |
| 2016-01-08 | $60.0M | B | Multiple | Article |
| 2017-07-25 | $30.0M | C | Tiger Partners | Article |